Alpha-emitting radionuclides for use in the treatment of peritoneal cancer
AssigneeOncoinvent AS
InventorRoy Hartvig Larsen
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical compositions comprising a therapeutically relevant amount of alpha emitting radionuclides, for use in the treatment of cancer, and specifically where the individual has received cytoreductive surgery of one or more peritoneal tumor(s) prior to the administration of the pharmaceutical composition.
Claims16
A pharmaceutical composition comprising a therapeutically effective amount of alpha emitting radionuclides, wherein the alpha emitting radionuclides are at a dosage that can be administered with a radiation dose range of 6 Gy (30 Sv) to 2000 Gy (10 000 Sv).
2-23. (canceled)
A particle of numerical diameter size 0.1-30 micron radiolabelled with 1-2000 atoms of alpha emitter per particle.
Dependencies are inferred from the claim text.